Teva announced the launch of an authorized generic of Flector Patch, 1.3 %, in the U.S. Diclofenac Epolamine Topical Patch, 1.3%, a nonsteroidal anti-inflammatory drug, is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions. Diclofenac Epolamine Topical Patch, 1.3% is contraindicated in patients with known hypersensitivity to diclofenac or any components of the drug product. Diclofenac Epolamine Topical Patch, 1.3% is contraindicated in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. Diclofenac Epolamine Topical Patch, 1.3% is contraindicated for use on non-intact or damaged skin resulting from any etiology, including, exudative dermatitis, eczema, infected lesions, burns, or wounds.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.